London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Doc D revisionary nonsense on vaccines let’s finally put it to bed
He says “ they were designing a trial that would start in early 2021. At the time they started thinking about the design, every newspaper in the world and every news bulletin was full of reports of the accelerated programmes that would deliver the vaccines in record time”
The reality is our trial was of course a follow on phase 3 to a trial already designed under phase 2. So the work on this trial had largely already been done by July 2020
when we started talking to regulators.
So what was being said in Oct of 2020 about vaccines?
https://www.bmj.com/company/newsroom/covid-19-vaccine-trials-cannot-tell-us-if-they-will-save-lives/
An interview with the chief scientific officer at Moderna
“None of the trials currently underway are designed to detect a reduction in any serious outcome such as hospitalisations, intensive care use, or deaths. Nor are the vaccines being studied to determine whether they can interrupt transmission of the virus”
Moderna called hospitalisations a “key secondary endpoint” in statements to the media. But Tal Zaks, Chief Medical Officer at Moderna, told The BMJ that their trial lacks adequate statistical power to assess that endpoint.
Part of the reason may be numbers, says Doshi. Because most people with symptomatic covid-19 infections experience only mild symptoms, even trials involving 30,000 or more patients would turn up relatively few cases of severe disease.
“Hospitalisations and deaths from covid-19 are simply too uncommon in the population being studied for an effective vaccine to demonstrate statistically significant differences in a trial of 30,000 people,” he adds. “The same is true regarding whether it can save lives or prevent transmission: the trials are not designed to find out.”
The truth is the virus mutated, it became less severe and SOC got better that’s what caused our primary end point failure and thats why almost 2 years later in 2022 scientist realised trials needed redesigning.
In summary, we've blown £85M. Had no apology, no concrete plan, limited communications and increased salaries for the board,
They raised money to run a trial
They ran a trial
Well done Mr C you understand the basics
There must be some point at which this company has to say something..statutory results or similar. Anyone know. One might easily form a view that Marsden spends his day doing nothing and being handsomely paid for doing nothing and is happy to do so until all the money (non contributed by him) is frittered away. But he is working 'at haste'. LOL.
Your posting history shows a long litany of complaints in every company you've "invested" in. Can't fathom how anyone puts money into every company they utterly despise. Perplexing.
We have probably reached the point where it is too late to commence P2 trials during Q2, 2024. The poster presentation at ATS 2024 was sadly just that. I had hoped that it would be quickly followed by an RNS statement concerning the proposed trials.
Like some other investors, I have all but given up on the CEO and his executives. They evidently lack the ability and wherewithal to take SNG001 forward to further trialling. Nothing of any material benefit to investors has happened as the result of their assumed activity over the last 27 months.
Our best hope appears to lie with TFG Holdings, and their next steps. Should they “persuade” the company to place their valuable IP in the hands of a major biopharmaceutical entity to everyone’s benefit, we may have an opportunity of recouping some of our losses? Perhaps I am being naive in thinking that anything of this nature could happen?
As always, I shall, as ever, be happy to learn that my pessimism regarding the company’s leadership was incorrect, and unfounded. A long running saga, with nothing whatsoever achieved, and very little dialogue with investors has brought this about.
GLALTIs.
Hayashi - we should any day now get full year results, annual report and AGM.
Https://activ-biorep.org/
NIH Activ
These trials have generated biospecimens that could be critical research resources for further studies elucidating the pathobiology of COVID-19 and potentially identifying therapeutic targets.
While biospecimens are currently stored by each ACTIV study biorepository, this central web-based virtual biorepository portal provides a readily searchable systematic inventory of the samples and associated meta-data as well as the ability to apply for access to these biospecimens.
Access now being granted to researchers